Ganitumab (AMG 479) is a highly potent monoclonal antibody targeting the type 1 insulin-like growth factor receptor (IGF1R). Recognized for binding IGF1R at low concentrations with a KD value of 0.22 nM, Ganitumab inhibits IGF1R interactions with IGF1 and IGF2 in mice, making it useful for cancer research.

Ganitumab (AMG 479; 0.032-500 nM; 10 minutes; cT26 cells) binds to mIGF1R, inhibiting its activation mediated by IGF1 and IGF2[1].

In naive and tumor-bearing mice, ganitumab (AMG 479; 1 mg/dose; i.p.) inhibited IGF1-induced activation of mIGF1R in mouse lung[1].
In female thymusless nude mice, ganitumab (300 μg/dose; i.p.) reduced peripheral blood neutrophils[1].
In male athymic nude mice, ganitumab (300 μg/dose; i.p.) resulted in impaired glucose tolerance and increased serum mGH, mIGF1, and mIGFBP3[1].

Human

Monoclonal

Unconjugated